An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood.
MET
biomarker
circulating tumor cells
epithelial cell adhesion molecule (EpCAM)
liquid biopsy
Journal
Micromachines
ISSN: 2072-666X
Titre abrégé: Micromachines (Basel)
Pays: Switzerland
ID NLM: 101640903
Informations de publication
Date de publication:
30 May 2020
30 May 2020
Historique:
received:
30
04
2020
revised:
22
05
2020
accepted:
26
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
Here, we validated the clinical utility of our previously developed microfluidic device, GenoCTC, which is based on bottom magnetophoresis, for the isolation of circulating tumor cells (CTCs) from patient whole blood. GenoCTC allowed 90% purity, 77% separation rate, and 80% recovery of circulating tumor cells at a 90 μL/min flow rate when tested on blood spiked with epithelial cell adhesion molecule (EpCAM)-positive Michigan Cancer Foundation-7 (MCF7) cells. Clinical studies were performed using blood samples from non-small cell lung cancer (NSCLC) patients. Varying numbers (2 to 114) of CTCs were found in each NSCLC patient, and serial assessment of CTCs showed that the CTC count correlated with the clinical progression of the disease. The applicability of GenoCTC to different cell surface biomarkers was also validated in a cholangiocarcinoma patient using anti-EPCAM, anti-vimentin, or anti-tyrosine protein kinase MET (c-MET) antibodies. After EPCAM-, vimentin-, or c-MET-positive cells were isolated, CTCs were identified and enumerated by immunocytochemistry using anti-cytokeratin 18 (CK18) and anti-CD45 antibodies. Furthermore, we checked the protein expression of PDL1 and c-MET in CTCs. A study in a cholangiocarcinoma patient showed that the number of CTCs varied depending on the biomarker used, indicating the importance of using multiple biomarkers for CTC isolation and enumeration.
Identifiants
pubmed: 32486306
pii: mi11060560
doi: 10.3390/mi11060560
pmc: PMC7345362
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Hun Seok Lee, Juhyun Hwang, and Young Kee Shin own stock in Genobio Corp. No potential conflict of interests was disclosed by other authors.
Références
Oncogene. 2016 Mar 10;35(10):1216-24
pubmed: 26050619
Nature. 2007 Dec 20;450(7173):1235-9
pubmed: 18097410
Chem Eng Sci. 2011 Apr 1;66(7):1508-1522
pubmed: 21532971
Anal Chem. 2013 Mar 5;85(5):2779-86
pubmed: 23384087
Mol Oncol. 2016 Mar;10(3):374-94
pubmed: 26897752
Clin Cancer Res. 2019 Apr 15;25(8):2403-2413
pubmed: 30425090
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Ann Transl Med. 2015 Mar;3(3):36
pubmed: 25815297
PLoS One. 2016 Feb 09;11(2):e0149315
pubmed: 26859839
Cancer Sci. 2014 Aug;105(8):1002-7
pubmed: 24863535
Mol Oncol. 2015 Nov;9(9):1773-82
pubmed: 26093818
PLoS One. 2013 Apr 23;8(4):e61770
pubmed: 23626725
Small. 2014 Dec 10;10(23):4895-904
pubmed: 25074448
Mol Cancer. 2017 Apr 14;16(1):80
pubmed: 28410618
Ann Transl Med. 2014 Nov;2(11):108
pubmed: 25489582
Br J Cancer. 2007 Feb 12;96(3):417-23
pubmed: 17211480
Hepatology. 2016 Jan;63(1):148-58
pubmed: 26096702
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Int J Cancer. 2013 Nov;133(9):2165-71
pubmed: 23616258
J Am Chem Soc. 2017 Feb 22;139(7):2741-2749
pubmed: 28133963
Am J Pathol. 2000 Jan;156(1):57-63
pubmed: 10623654
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Sci Rep. 2019 Dec 3;9(1):18195
pubmed: 31796846
J Clin Oncol. 2009 Nov 1;27(31):5153-9
pubmed: 19752342
Acta Oncol. 2011 Jun;50(5):700-10
pubmed: 21261508
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18165-70
pubmed: 19015523
Breast Cancer Res. 2007;9(5):R74
pubmed: 17963511
Invest New Drugs. 2018 Jun;36(3):416-423
pubmed: 29047029
Oncotarget. 2016 Mar 15;7(11):12748-60
pubmed: 26863573
NPJ Precis Oncol. 2017 May 8;1(1):15
pubmed: 29872702
Eur Urol. 2011 Sep;60(3):578-84
pubmed: 21704449
PLoS One. 2013 Jun 27;8(6):e67148
pubmed: 23826219
Clin Chem. 2014 Feb;60(2):287-9
pubmed: 24323980
Oncoimmunology. 2018 Mar 6;7(7):e1438111
pubmed: 29900038
BMC Cancer. 2015 Oct 24;15:797
pubmed: 26498594
Sci Rep. 2016 Jun 15;6:28010
pubmed: 27302574
Langmuir. 2004 Feb 3;20(3):572-4
pubmed: 15773077
Sci Rep. 2016 Jul 01;6:28910
pubmed: 27363678
PLoS One. 2014 Jan 08;9(1):e85264
pubmed: 24416373
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Invest New Drugs. 2018 Oct;36(5):886-894
pubmed: 29766337
J Transl Med. 2019 Aug 28;17(1):294
pubmed: 31462312
Sci Rep. 2015 Jul 17;5:12270
pubmed: 26184843
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Cancer Res. 2009 Jul 15;69(14):5627-9
pubmed: 19584271
J Clin Endocrinol Metab. 2016 Nov;101(11):4461-4467
pubmed: 27575943
Ann Oncol. 2010 Sep;21(9):1851-1857
pubmed: 20147742
Cancer Lett. 2007 Apr 18;248(2):219-28
pubmed: 16945480
Chem Sci. 2017 Mar 1;8(3):1736-1751
pubmed: 28451298
Nat Biotechnol. 2014 May;32(5):479-84
pubmed: 24752078
Cancer Treat Rev. 2012 Feb;38(1):68-75
pubmed: 21576002
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
Anal Chem. 2010 Aug 1;82(15):6629-35
pubmed: 20583799
Oncotarget. 2017 Apr 18;8(16):26112-26121
pubmed: 28212540
BMC Cancer. 2013 Apr 23;13:202
pubmed: 23617715
Lab Chip. 2012 Apr 21;12(8):1471-9
pubmed: 22395226
Breast Cancer Res Treat. 2009 Dec;118(3):523-30
pubmed: 19597704
Lab Chip. 2014 Jan 7;14(1):32-44
pubmed: 23963515
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7
pubmed: 20930119
J Clin Oncol. 2018 Nov 1;36(31):3101-3109
pubmed: 30156984
Lab Chip. 2014 Jan 7;14(1):128-37
pubmed: 23949794
Expert Rev Mol Diagn. 2011 Jun;11(5):473-85
pubmed: 21707456